Clinical Trials & Research

Driven to apply our scientific insights to develop medicines that improve the lives of patients with rare metabolic disorders.

Overview

Selecta Biosciences is a clinical stage biotechnology company with a commitment to solving the challenges associated with autoimmunity and unwanted immunogenicity through our pioneering ImmTOR® precision immune tolerance platform.

Research & Studies

NIH Protocol Details – A Phase 1/2, Open-Label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 (MMA-101 following administration of SEL-110) in Pediatric Subjects with Mut Subtype Isolated Methylmalonic Acidemia (MMA)

The reiMMAgine trial is a Phase 1/2 study which aims to investigate how children diagnosed with mut subtype isolated MMA respond to the gene therapy SEL-302 (a combination of SEL-110 and MMA-101), and if the study medication will help with their symptoms.

Articles from previous OAA newsletters:

​Successful Gene Therapy Treatment and Redosing in an Animal Model of Methylmalonic Acidemia

Recent Articles

Winter 2023 OAA Newsletter (Digital Version Available Now!)
April 5, 2023
2023 OAA Fundraising Calendar Ready to Purchase
November 10, 2022
Update on the Rapid Blood Ammonia Testing Instrument
June 5, 2023
Katie – Glutaric Acidemia, Type 1
May 4, 2023
Abbott Formula Update – April 24, 2023
April 24, 2023
Contact Us

Website: https://selectabio.com/

Select Language